Key Highlights

  • PepGen (NASDAQ:PEPG) closed up 92.89% at about USD 4.61 on November 10, 2026, after trading more than 120% higher early in the session.
  • In the FREEDOM2-DM1 Phase 2 trial, four monthly doses of PGN-EDODM1 at 10 mg/kg produced mean splicing correction of 46.5%, against 6.8% for placebo.
  • The company called it the highest splicing correction reported in a multiple-dose study in myotonic dystrophy type 1, with no serious adverse events.
  • After the close, PepGen proposed a USD 125 million public offering, and the shares still added about 14% on November 11.

What the Trial Showed

Myotonic dystrophy type 1 is an inherited neuromuscular disease in which a toxic RNA traps proteins that regulate splicing, causing muscle weakness, delayed muscle relaxation and heart problems. There is no approved disease-modifying therapy. PepGen's candidate, PGN-EDODM1, is designed to release those proteins and restore normal splicing. In the randomised, double-blind, placebo-controlled 10 mg/kg cohort, eight patients were randomised three to one, so six received the drug. After four monthly infusions, mean splicing correction in muscle reached 46.5% at week 13, compared with 6.8% for pooled placebo. Five of six treated patients exceeded 20% correction and four exceeded 50%, a sharp step up from 7.3% in the earlier 5 mg/kg cohort. Functional measures moved in the right direction, including a 3.9 second improvement in hand opening time, about 16% better grip strength and gains in timed walking tests, including an 8.5% improvement in the timed up and go test. Because splicing correction is a direct measure of the drug's mechanism, investors viewed the dose response as strong evidence that the approach works.

Safety and Caveats

Tolerability was encouraging. All treatment-emergent adverse events in the cohort were mild or moderate, with no serious events and no discontinuations, and nausea was the most common side effect. Four mild kidney-related events were reported, and one patient in the open-label extension discontinued after a hypersensitivity reaction. The caveats are significant. The cohort is very small, so the functional findings are early signals rather than proof of clinical benefit. In addition, a partial clinical hold placed in the United States in March 2026 must be lifted before PepGen can hold an end of Phase 2 meeting, planned for the second half of 2027. A competitor's registrational data, expected in early 2027, will also set a benchmark for the field. Even so, the magnitude of splicing correction is what drove the re-rating of PepGen (NASDAQ:PEPG).

The Capital Raise and Next Steps

The company moved quickly to fund development. After the close on November 10 it proposed a USD 125 million public offering of common stock, using an effective shelf registration, to fund clinical development and general corporate purposes. Before the raise, PepGen held USD 104.8 million of cash and securities at September 30, 2026, which it said would fund operations into 2028, so the new money extends the runway further. Dilution often weighs on biotech stocks after a data-driven surge, but the shares rose about 14% on November 11, suggesting strong demand. Upcoming milestones include interim open-label extension data in January 2027, results from a fully enrolled 12.5 mg/kg cohort in the first half of 2027 and progress on resolving the clinical hold. Investors will also watch whether higher doses improve correction further without new safety signals.

Where Things Stand

PepGen (NASDAQ:PEPG) nearly doubled on November 10, 2026 after its 10 mg/kg cohort showed 46.5% mean splicing correction in myotonic dystrophy type 1 with a clean safety profile. A USD 125 million offering followed, yet shares rose further the next day. Small patient numbers, the partial clinical hold and competitor data are the key risks ahead.